Frontiers in Pharmacology (Feb 2024)
Lung cancer, comorbidities, and medication: the infernal trio
- Hélène Pluchart,
- Hélène Pluchart,
- Hélène Pluchart,
- Sébastien Chanoine,
- Sébastien Chanoine,
- Sébastien Chanoine,
- Denis Moro-Sibilot,
- Denis Moro-Sibilot,
- Denis Moro-Sibilot,
- Christos Chouaid,
- Christos Chouaid,
- Gil Frey,
- Julie Villa,
- Bruno Degano,
- Bruno Degano,
- Bruno Degano,
- Matteo Giaj Levra,
- Matteo Giaj Levra,
- Pierrick Bedouch,
- Pierrick Bedouch,
- Pierrick Bedouch,
- Anne-Claire Toffart,
- Anne-Claire Toffart,
- Anne-Claire Toffart
Affiliations
- Hélène Pluchart
- Pôle Pharmacie, Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, France
- Hélène Pluchart
- Université Grenoble Alpes, Grenoble, France
- Hélène Pluchart
- Université Grenoble Alpes, CNRS, Grenoble INP, TIMC UMR5525, Grenoble, France
- Sébastien Chanoine
- Pôle Pharmacie, Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, France
- Sébastien Chanoine
- Université Grenoble Alpes, Grenoble, France
- Sébastien Chanoine
- Institut pour l’Avancée des Biosciences, UGA/INSERM U1209/CNRS 5309, Université Grenoble Alpes, La Tronche, France
- Denis Moro-Sibilot
- Université Grenoble Alpes, Grenoble, France
- Denis Moro-Sibilot
- Institut pour l’Avancée des Biosciences, UGA/INSERM U1209/CNRS 5309, Université Grenoble Alpes, La Tronche, France
- Denis Moro-Sibilot
- Service Hospitalier Universitaire de Pneumologie Physiologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
- Christos Chouaid
- Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, Créteil, France
- Christos Chouaid
- Inserm U955, UPEC, IMRB, équipe CEpiA, CréteilFrance
- Gil Frey
- Service de Chirurgie Thoracique, Vasculaire et Endocrinienne, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
- Julie Villa
- Service de Radiothérapie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
- Bruno Degano
- Université Grenoble Alpes, Grenoble, France
- Bruno Degano
- Service Hospitalier Universitaire de Pneumologie Physiologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
- Bruno Degano
- 0Laboratoire HP2, INSERM U1042, Université Grenoble Alpes, Grenoble, France
- Matteo Giaj Levra
- Institut pour l’Avancée des Biosciences, UGA/INSERM U1209/CNRS 5309, Université Grenoble Alpes, La Tronche, France
- Matteo Giaj Levra
- Service Hospitalier Universitaire de Pneumologie Physiologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
- Pierrick Bedouch
- Pôle Pharmacie, Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, France
- Pierrick Bedouch
- Université Grenoble Alpes, Grenoble, France
- Pierrick Bedouch
- Université Grenoble Alpes, CNRS, Grenoble INP, TIMC UMR5525, Grenoble, France
- Anne-Claire Toffart
- Université Grenoble Alpes, Grenoble, France
- Anne-Claire Toffart
- Institut pour l’Avancée des Biosciences, UGA/INSERM U1209/CNRS 5309, Université Grenoble Alpes, La Tronche, France
- Anne-Claire Toffart
- Service Hospitalier Universitaire de Pneumologie Physiologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
- DOI
- https://doi.org/10.3389/fphar.2023.1016976
- Journal volume & issue
-
Vol. 14
Abstract
Most patients with lung cancer are smokers and are of advanced age. They are therefore at high risk of having age- and lifestyle-related comorbidities. These comorbidities are subject to treatment or even polypharmacy. There is growing evidence of a link between lung cancer, comorbidities and medications. The relationships between these entities are complex. The presence of comorbidities and their treatments influence the time of cancer diagnosis, as well as the diagnostic and treatment strategy. On the other hand, cancer treatment may have an impact on the patient’s comorbidities such as renal failure, pneumonitis or endocrinopathies. This review highlights how some comorbidities may have an impact on lung cancer presentation and may require treatment adjustments. Reciprocal influences between the treatment of comorbidities and anticancer therapy will also be discussed.
Keywords